| [1] |
Fitzsimmons TS, Singh N, Walker TDJ, et al. Immune checkpoint inhibitors efficacy across solid cancers and the utility of PD-L1 as a biomarker of response:a systematic review and meta-analysis[J]. Front Med, 2023, 10:1192762.
DOI
URL
|
| [2] |
Albastaki E, Rishu RS, Tun Y, et al. Triple M syndrome after immune checkpoint inhibition:a rare and life-threatening triad of myocarditis,myositis,and myasthenia gravis[J]. Cureus, 2025, 17(11):e96514.
|
| [3] |
Pathak R, Katel A, Massarelli E, et al. Immune checkpoint inhibitor-induced myocarditis with myositis/myasthenia gravis overlap syndrome:a systematic review of cases[J]. Oncologist, 2021, 26(12):1052-1061.
DOI
URL
|
| [4] |
Furlepa M, Watts I, Carr AS. Management of triple M syndrome:a narrative review of immune checkpoint inhibitor-induced myasthenia gravis,myositis and myocarditis[J]. Cancers, 2025, 17(13):2063.
DOI
URL
|
| [5] |
Weaver JM, Dodd K, Knight T, et al. Improved outcomes with early immunosuppression in patients with immune-checkpoint inhibitor induced myasthenia gravis,myocarditis and myositis:a case series[J]. Support Care Cancer, 2023, 31(9):518.
DOI
PMID
|
| [6] |
中国医师协会呼吸医师分会, 中国医师协会肿瘤多学科诊疗专业委员会. 免疫检查点抑制剂相关毒性防治与管理建议[J]. 中华医学杂志, 2022, 102(24):1811-1832.
|
|
Respiratory Physician Branch of Chinese Medical Doctor Association, Multidisciplinary Diagnosis and Treatment Committee of Chinese Medical Doctor Association. Suggestions on prevention and management of related toxicity of inhibitors at immune checkpoint[J]. Natl Med J China, 2022, 102(24):1811-1832.
|
| [7] |
National Comprehensive Cancer Network. (2025). NCCN clinical practice guidelines in oncology:management of immune checkpoint inhibitor-related toxicities?(Version 1.2025)[EB/OL]. (2024-12-20)[2026-01-05]. https://www.geoq.info/pub/documents/IMMUNOTHERAPIE/immunotherapie_lignes-directrices_238.pdf.
|
| [8] |
徐南娇, 胡蕾. 1例免疫检查点抑制剂相关重症心肌炎患者合并心源性休克的护理[J]. 中华护理杂志, 2022, 57(17):2141-2144.
DOI
|
|
Xu NJ, Hu L. Nursing care of a patient with immune checkpoint inhibitors related cardiogenic shock after acute fulminant myocarditis[J]. Chin J Nurs, 2022, 57(17):2141-2144.
DOI
|
| [9] |
邱小英, 石泽亚, 张艳, 等. 1例免疫检查点抑制剂相关暴发性心肌炎患者的护理[J]. 中华护理杂志, 2022, 57(14):1744-1748.
DOI
|
|
Qiu XY, Shi ZY, Zhang Y, et al. Nursing care of a patient with immune checkpoint inhibitor-associated fulminant myocarditis[J]. Chin J Nurs, 2022, 57(14):1744-1748.
DOI
|
| [10] |
中华医学会神经病学分会神经免疫学组. 中国重症肌无力诊断和治疗指南(2025版)[J]. 中华神经科杂志, 2025, 58(7):721-741.
|
|
Neuroimmunology Group, Neurology Branch, Chinese Medical Association. Chinese guideline for diagnosis and treatment of myasthenia gravis(2025 edition)[J]. Chin J Neurol, 2025, 58(7):721-741.
|
| [11] |
Cuenca JA, Hanmandlu A, Wegner R, et al. Management of respiratory failure in immune checkpoint inhibitors-induced overlap syndrome:a case series and review of the literature[J]. BMC Anesthesiol, 2023, 23(1):310.
DOI
PMID
|
| [12] |
罗苏珊, 周昊, 岳耀先, 等. 重症肌无力危象前状态管理专家共识(2024)[J]. 中国临床神经科学, 2024, 32(3):241-251.
|
|
Luo SS, Zhou H, Yue YX, et al. Expert consensus on the management of impending myasthenic crisis(2024)[J]. Chin J Clin Neurosci, 2024, 32(3):241-251.
|
| [13] |
中华医学会内分泌学分会, 中国内分泌代谢病专科联盟. 糖皮质激素类药物临床应用指导原则(2023版)[J]. 中华内分泌代谢杂志, 2023, 39(4):289-296.
|
|
Chinese Society of Endocrinology, China Endocrinology and Metabolism Specialist Alliance. Principles for clinical application of glucocorticoids(2023 edition)[J]. Chin J Endocrinol Metab, 2023, 39(4):289-296.
|
| [14] |
Sánchez-Camacho A, Torres-Zurita A, Gallego-López L, et al. Management of immune-related myocarditis,myositis and myasthenia gravis(MMM) overlap syndrome:a single institution case series and literature review[J]. Front Immunol, 2025, 16:1597259.
DOI
URL
|
| [15] |
Lipe DN, Qdaisat A, Krishnamani PP, et al. Myocarditis,myositis,and myasthenia gravis overlap syndrome associated with immune checkpoint inhibitors:a systematic review[J]. Diagnostics, 2024, 14(16):1794.
DOI
URL
|